Condition: Advanced Solid Tumor · Advanced Solid Malignancies · Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.
This description comes directly from the study's public registry record.
Liting Lai · 8617728075858 · vivi.lai@ming-med.com
Always discuss trial participation with your own doctor first.
| The first affiliated hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Cancer hospital of the University of Chinese Academy of Sciences | Hangzhou, Zhejiang, China | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| The Fifth Medical Center of PLA General Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05315167